{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:26:57Z","timestamp":1784359617512,"version":"3.55.0"},"reference-count":145,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["BIOT"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS--\nCoV-2) is an RNA virus involving 4 structural and 16 non-structural proteins and exhibiting\nhigh transmission potential and fatality. The emergence of this newly encountered beta\ncoronavirus-SARS-CoV-2 has caused over 2 million deaths, and more than 10 billion\npeople got infected across the globe as yet. Consequently, the global scientific community\nhas contributed to synthesizing and designing effective immunization technologies to\ncombat this virus.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>This literature review intended to gather an update on published reports of\nthe vaccines advancing in the clinical trial phases or pre-clinical trials to summarize the\nfoundations and implications of contributing vaccine candidates inferring their impact on\nthe pandemic repression. In addition, this literature review distinctly provides an outline\nof the overall vaccine effectiveness at current doses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The reported data in this review were extracted from research articles, review\narticles, and patents published from January 2020 to July 2021, available on Google\nScholar, Pubmed, Pubmed Central, Research Gate, and ScienceDirect by using a combination\nof keywords. Moreover, some information was retrieved from the web pages of\nvaccine manufacturing companies due to progressing research and the unavailability of\npublished research papers.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Contributing vaccine technologies include RNA (Ribonucleic acid)\nvaccines, DNA (Deoxyribonucleic acid) vaccines, viral vector vaccines, protein-based\nvaccines, inactivated vaccines, viruses-like particles, protein superglue, and live-attenuated\nvaccines. Some vaccines are prepared by establishing bacterial and yeast cell lines and\nself-assembling adenovirus-derived multimeric protein-based self-assembling nanoparticles\n(ADDOmer). On May 19th, WHO has issued an emergency use sanction of Moderna,\nPfizer, Sinopharm, AstraZeneca, and Covishield vaccine candidates on account of clinical\ncredibility from experimental data.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872208316666220118094344","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T04:07:50Z","timestamp":1642565270000},"page":"122-143","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["An Outline of Contributing Vaccine Technologies for SARS CoV2\nAdvancing in Clinical and Preclinical Phase-Trials"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-5135","authenticated-orcid":true,"given":"Sheikh Saba","family":"Naz","sequence":"first","affiliation":[{"name":"Department of Microbiology, Jinnah University for Women, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Munir","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Jinnah University for Women, Pakistan"},{"name":"National Nanotechnology Research\nCenter-UNAM, Bilkent University, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","volume":"10","author":"Wang M.Y.","year":"2020","unstructured":"Wang M.Y.; Zhao R.; Gao L.J.; Gao X.F.; Wang D.P.; Cao J.M.; SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020,10,587269","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2020.03.20.000141","DOI":"10.1101\/2020.03.20.000141","author":"Ong E.","year":"2020","unstructured":"Ong E.; Wong M.U.; Huffman A.; He Y.; COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. bioRxiv 2020,2020.03.20.000141","journal-title":"bioRxiv"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12931-020-01479-w","volume":"21","author":"Zhu Z.","year":"2020","unstructured":"Zhu Z.; Lian X.; Su X.; Wu W.; Marraro G.A.; Zeng Y.; From SARS and MERS to COVID-19: a brief sum-mary and comparison of severe acute respiratory in-fections caused by three highly pathogenic human coronaviruses. Respir Res 2020,21(1),224","journal-title":"Respir Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e1006254","DOI":"10.1371\/journal.ppat.1006254","volume":"13","author":"Smith E.C.","year":"2017","unstructured":"Smith E.C.; The not-so-infinite malleability of RNA viruses: Viral and cellular determinants of RNA virus mutation rates. PLoS Pathog 2017,13(4),e1006254","journal-title":"PLoS Pathog"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"Shang J.","year":"2020","unstructured":"Shang J.; Wan Y.; Luo C.; Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci USA 2020,117(21),11727-11734","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=6","unstructured":"Healthcare workers. Centers for disease control and prevention. 2021. Available from:gov\/coronavirus\/2019-ncov\/hcp\/clinicalguidancemanagementpatients.\nhtml#:~:text=The\n%20incubation %20period %20for %20COVID,from\n%20exposure %20to %20symptoms\n%20onset."},{"key":"ref=7","unstructured":"Coronavirus update (Live): 109,448,208 cases and 2,412,815 deaths from Covid-19 virus pandemic - worldometer. 2021. Available from:(Accessed February\n15, 2021. https:\/\/www.-worldometers.info\/coronavirus\/"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/2666796701999201019154537","volume":"2","author":"Naz S.","year":"2021","unstructured":"Naz S.; Munir I.; An overview of the treatment contri-butions measured globally for Covid19 outbreak. Coronaviruses 2021,2(2),188-203","journal-title":"Coronaviruses"},{"key":"ref=9","unstructured":"COVID-19 vaccine tracker and landscape. 2021. Available from:(Accessed\nJuly 31, 2021). https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidatevaccines"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e924700","DOI":"10.12659\/MSM.924700","volume":"26","author":"Wang F.","year":"2020","unstructured":"Wang F.; Kream R.M.; S.jtefano GB. An evidence based perspective on mRNA-SARS-CoV-2 Vaccine Development. Med Sci Monit 2020,26,e924700","journal-title":"Med Sci Monit"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","year":"2020","unstructured":"A single immunization with nucleoside-modified mrna vac-cines elicits strong cellular and humoral immune re-sponses against SARS-CoV-2 in mice. Immunity LaczkA3 D, Hogan MJ, Toulmin SA, et al.2020,53(4),724-732.e7","journal-title":"Immunity"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"Jackson L.A.","year":"2020","unstructured":"Jackson L.A.; Anderson E.J.; Rouphael N.G.; An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020,383(20),1920-1931","journal-title":"N Engl J Med"},{"key":"ref=13","unstructured":"Moderna\u2019s work on a COVID-19 vaccine candidate. 2020. Available from:modernas-work-potential-vaccine-against-covid-19 (Accessed December 15, 2020). https:\/\/www.modernatx.com\/-"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","volume":"30","author":"Tai W.","year":"2020","unstructured":"Tai W.; Zhang X.; Drelich A.; A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res 2020,30(10),932-935","journal-title":"Cell Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMc2036242","volume":"384","author":"Skowronski D.M.","year":"2021","unstructured":"Skowronski D.M.; De Serres G.; Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2021,384(16),1576-1577","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"Sahin U.","year":"2020","unstructured":"Sahin U.; Muik A.; Derhovanessian E.; COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020,586(7830),594-599","journal-title":"Nature"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"Haas E.J.","year":"2021","unstructured":"Haas E.J.; Angulo F.J.; McLaughlin J.M.; Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cas-es, hospitalisations, and deaths following a nation-wide vaccination campaign in Israel: an observation-al study using national surveillance data. Lancet published correction appears in Lancet. 2021 Jul 17;398(10296):2122021,397(10287),1819-1829","journal-title":"Lancet"},{"key":"ref=18","unstructured":"CureVac AG. Coronavirus vaccine. U.S. Patents; 20210379181, September 12, 2021."},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","volume":"6","author":"Rauch S.","year":"2021","unstructured":"Rauch S.; Roth N.; Schwendt K.; Fotin-Mleczek M.; Mueller S.O.; Petsch B.; mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines 2021,6(1),57","journal-title":"NPJ Vaccines"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.09.20228551","author":"Kremsner P.","year":"2020","unstructured":"Kremsner P.; Mann P.; Bosch J.; Phase 1 assess-ment of the safety and immunogenicity of an mRNA- lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. medRxiv 2020","journal-title":"medRxiv"},{"key":"ref=21","unstructured":"CureVac final data from phase 2b\/3 trial of firstgeneration Covid-19 vaccine candidate, cvncov, demonstrates protection in age group of 18 to 60. 2021. Available from(Accessed August 14, 2021). https:\/\/www.curevac.com\/en\/2021\/06\/30\/curevac-final-data-from-phase-2b-3-trial-offirst-generation-covid-19-vaccine-candidate-cvncov- -demonstrates-protection-in-age-group-of-18-to-60\/"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"Zhang N.N.","year":"2020","unstructured":"Zhang N.N.; Li X.F.; Deng Y.Q.; A Thermostable mRNA vaccine against COVID-19. Cell 2020,182(5),1271-83.e16","journal-title":"Cell"},{"key":"ref=23","unstructured":"Walvax: mRNA \u2013 COVID19 vaccine tracker. 2020. Available from:>(Accessed December 19, 2020). https:\/\/covid19.trackvaccines.org\/- vaccines\/23\/"},{"key":"ref=24","unstructured":"Biopharma dealmakers, Arcturus-a clinical-stage mRNA therapeutics and vaccines company. 2021. Available from:(Accessed August 1, 2021). https:\/\/www.nature.com\/articles\/d43747-021-00073-3"},{"key":"ref=25","unstructured":"Ascending dose study of investigational SARS-CoV- -2 vaccine ARCT-021 in healthy adult subjects - full text view - ClinicalTrials.gov. 2020. Available from:(Accessed December 18, 2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04480957"},{"key":"ref=26","author":"O'dea S","unstructured":"O'dea S; Maguire M;  Engineering of dendritic cells for generation of vaccines against SARS-COV-2. U.S. Patents; 20210290757, September 23, 2021."},{"key":"ref=27","author":"Richard W.","unstructured":"Richard W.;   Dendritic human universal non-antigen educap vaccine. U.S. Patents; 20220016163, January 20, 2022."},{"key":"ref=28","unstructured":"Providence therapeutics reports supportive preclinical data for its COVID-19 Vaccine Candidate (PTXCOVID19- B). 2020. Available from:(Accessed December\n19, 2020). https:\/\/www. providencetherapeutics.com\/providence-therapeutics-reports-supportive-preclinical-data-for-its-covid-19-vaccine-candidate-ptx-covid19-b"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.11.443286","author":"Liu J.","year":"2021","unstructured":"Liu J.; Budylowski P.; Samson R.; Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.medRxiv [Preprint]2021"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.29.319061","author":"Baray J.C.","year":"2021","unstructured":"Baray J.C.; Khan M.R.; Mahmud A.;  BANCOVID, the first D614G variant mRNA-based vaccine candi-date against SARS-CoV-2 elicits neutralizing anti-body and balanced cellular immune response [Preprint]2021","journal-title":"BANCOVID, the first D614G variant mRNA-based vaccine candi-date against SARS-CoV-2 elicits neutralizing anti-body and balanced cellular immune response"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1016\/j.vaccine.2021.05.035","volume":"39","author":"Nag K.","year":"2021","unstructured":"Nag K.; Chandra Baray J.; Rahman Khan M.; An mRNA-based vaccine candidate against SARS-CoV- -2 elicits stable immuno-response with single dose. Vaccine 2021,39(28),3745-3755","journal-title":"Vaccine"},{"key":"ref=32","unstructured":"mRNA vaccines. Gennova biopharmaceuticals limited.\n2020. Available from: (Accessed December 20, 2020). https:\/\/gennova.bio\/mrnavaccines\/"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.14.337535","author":"Kalnin K.V.","year":"2020","unstructured":"Kalnin K.V.; Plitnik T.; Kishko M.; Zhang J.; Zhang D.; Beauvais A.; Anosova N.G.; Tibbitts T.; Dinapoli J.M.; Huang P.D.; Huleatt J.; Vincent D.; Fries K.; Karve S.; Goldman R.; Gopani H.; Dias A.; Tran K.; Zacharia M.; Gu X.; Boeglin L.; Chivukula S.; Swearingen R.; Lan-dolfi V.; Fu T.; Derosa F.; Casimiro D.; Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates. 2020"},{"key":"ref=34","unstructured":"The first demonstration of virus-like particles expressed from a modified mRNA cocktail. 2020. Available from: (Accessed December\n21, 2020). https:\/\/www.fudan.edu.cn\/https:\/\/www.fudan.edu.cn\/en\/2020\/0307\/c344a104281\/page.htm"},{"key":"ref=35","unstructured":"CNB C. L&#xED;neas de actuaci&#xF3;nfrente al SARS-CoV2 enel CNB-CSIC. 2020. Available from:(Accessed December 22, 2020). http:\/\/www.cnb.csic.es\/index.php\/es\/investigacion\/investigacion-sars-cov2"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","volume":"288","author":"Kaur S.P.","year":"2020","unstructured":"Kaur S.P.; Gupta V.; COVID-19 Vaccine: A compre-hensive status report. Virus Res 2020,288,198114","journal-title":"Virus Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"198114","DOI":"10.1016\/j.virusres.2020.198114","volume":"288","author":"Kaur SP","year":"2020","unstructured":"Kaur SP; Gupta V; COVID-19 Vaccine: A comprehensive\nstatus report.  Virus Res 2020,288,198114","journal-title":"Virus Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","volume":"11","author":"Smith T.R.F.","year":"2020","unstructured":"Smith T.R.F.; Patel A.; Ramos S.; Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 2020,11(1),2601","journal-title":"Nat Commun"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.07.21256652","author":"Mammen MP","year":"2021","unstructured":"Mammen MP; Tebas P; Agnes J; Safety and\nimmunogenicity of INO-4800 DNA vaccine against\nSARS-CoV-2: a preliminary report of a randomized,blinded, placebo-controlled, Phase 2 clinical trial in\nadults at high risk of viral exposure 2021"},{"key":"ref=40","unstructured":"Clinicaltrials.gov. 2020. Phase II \/ III Study Of COVID-19 DNA Vaccine (AG0302-COVID19) - Full Text View - Clinicaltrials.Gov. online Available atAccessed\n24 December 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04655625"},{"key":"ref=41","unstructured":"Clinicaltrials.gov. 2020. Safety And Immunogenicity Study Of GX-19, A COVID-19 Preventive DNA Vaccine In Healthy Adults - Full Text View - Clinicaltrials. Gov. [online] Available at:Accessed 25 December\n2020 https:\/\/clinicaltrials. gov\/ct2\/show\/NCT04445389"},{"key":"ref=42","unstructured":"Covid-19 and the SymvivobacTRL Platform. Symvivo. com.Published 2020. Accessed December 26, 2020 https:\/\/www.symvivo.com\/covid-19"},{"key":"ref=43","unstructured":"Evaluating the safety, tolerability, and immunogenicity of BACTRL-spike vaccine for prevention of COVID-19 - Full Text View - ClinicalTrials.gov. Clinicaltrials.gov. Published 2020. Accessed December 26, 2020 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04334980"},{"key":"ref=44","unstructured":"CORVax12: SARS-CoV-2 Spike (S) protein plasmid DNA vaccine trial for COVID-19 (SARS-CoV-2) - Full Text View - ClinicalTrials.gov. Clinicaltrials. gov.Published 2020. Accessed December 26, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04627675"},{"key":"ref=45","unstructured":"A clinical trial of a plasmid dna vaccine for COVID- 19 [Covigenix VAX-001] in adults - full text view - ClinicalTrials.gov. Clinicaltrials.gov.Published 2020. Accessed December 30, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04591184"},{"key":"ref=46","unstructured":"Recruitment update for the phase 1 clinical trial of entos\u2019 made in Canada DNA vaccine for COVID-19. 2021. Available from:https:\/\/www.entospharma.- com\/news\/recruitment-update-for-the-phase-1- clinical-trial-of-entos-made-in-canada-dna-vaccineforcovid- 19(Accessed August 2, 2021)."},{"key":"ref=47","unstructured":"Cambridge-developed SARS-CoV-2 vaccine receives &#xA3;1.9million from the UK government for the clinical trial. 2020. Available from: (Accessed December 27,2020). https:\/\/www.-cam.ac.uk\/research\/news\/cambridge-developed-sarscov-2-vaccine-receives-ps19million-from-uk-government-for-clinical-trial"},{"key":"ref=48","author":"University N.","unstructured":"University N.;  Universities in Nottingham to play a key role in the development of a potential DNA vaccine against COVID-192020 Avaialble from: (Accessed December 28,\n2020). https:\/\/www.ntu.ac.uk\/about-us\/news\/newsarticles\/\n2020\/04\/universities-in-nottingham-to-playakey-\nrole-in-the-development-of-a-potential-dna-\nvaccine-against-covid-19","journal-title":"Universities in Nottingham to play a key role in the development of a potential DNA vaccine against COVID-192020 Avaialble from:"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1080\/21645515.2020.1825896","volume":"16","author":"Rabaan A.A.","year":"2020","unstructured":"Rabaan A.A.; Al-Ahmed S.H.; Sah R.; Recent ad-vances in vaccine and immunotherapy for COVID-19. Hum Vaccin Immunother 2020,16(12),3011-3022","journal-title":"Hum Vaccin Immunother"},{"key":"ref=50","unstructured":"News Events - BioNet. 2020. Available from:(\nAccessed December 29, 2020). http:\/\/www.bionet-asia.com\/media\/news-events\/"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.08.416875","author":"Norheim G.","year":"2020","unstructured":"Norheim G.; Stubsrud E.; Skullerud L.M.;  bioRxiv 2020","journal-title":"bioRxiv"},{"key":"ref=52","unstructured":"Positive preclinical results from vaccine candidates for COVID-19. Applied DNA Sciences. 2020. Available from:(Accessed\nDecember 29, 2020). https:\/\/adnas.com\/covid19-vaccines\/"},{"key":"ref=53","unstructured":"The University of Waterloo developing DNA-based COVID-19 vaccine | Waterloo Stories. Waterloo Stories. 2020. Available from:(Accessed\nDecember 30, 2020). https:\/\/uwaterloo.ca\/stories\/news\/university-waterloo-developing-dna-based-covid-19-vaccine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","volume":"19","author":"van Riel D.","year":"2020","unstructured":"van Riel D.; de Wit E.; Next-generation vaccine plat-forms for COVID-19. Nat Mater 2020,19(8),810-812","journal-title":"Nat Mater"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","volume":"27","author":"Barrett J.R.","year":"2021","unstructured":"Barrett J.R.; Belij-Rammerstorfer S.; Dold C.; Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody re-sponses. Nat Med Ox-ford COVID Vaccine Trial Group2021,27(2),279-288","journal-title":"Nat Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"Voysey M.","year":"2021","unstructured":"Voysey M.; Clemens S.A.C.; Madhi S.A.; Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Oxford COVID Vaccine Trial Group2021,397(10269),99-111","journal-title":"Lancet"},{"key":"ref=57","unstructured":"Phase III trial of a COVID-19 vaccine of adenovirus vector in adults 18 years old and above - full text view - clinicaltrials.gov. Available from:(Accessed January 2, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04526990"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"Zhu F.C.","year":"2020","unstructured":"Zhu F.C.; Guan X.H.; Li Y.H.; Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet 2020,396(10249),479-488","journal-title":"Lancet"},{"key":"ref=59","unstructured":"The Lancet: Preliminary results from Russian trials of vaccine candidates reported. EurekAlert!. 2021. Available from:(Accessed January 2, 2021). https:\/\/www.eurekalert.org\/pub_releases\/2020-09\/tl-tlp090420.php"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"Logunov D.Y.","year":"2020","unstructured":"Logunov D.Y.; Dolzhikova I.V.; Zubkova O.V.; Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 2020,396(10255),887-897","journal-title":"Lancet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","volume":"397","author":"Jones I.","year":"2021","unstructured":"Jones I.; Roy P.; Sputnik V COVID-19 vaccine candi-date appears safe and effective. Lancet 2021,397(10275),642-643","journal-title":"Lancet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"m4451","DOI":"10.1136\/bmj.m4451","volume":"371","author":"Torjesen I.","year":"2020","unstructured":"Torjesen I.; Covid-19: Third candidate vaccine will be tested in the UK. BMJ 2020,371,m4451","journal-title":"BMJ"},{"key":"ref=63","author":"Lederman S.","year":"2021","unstructured":"Lederman S.; Goebel S.; Evans D.; Noyce R.;  Recombinant Poxvirus Based Vaccine Against SARS-CoV-2 virus. U.S. Patent; 20210260182, August 26,2021"},{"key":"ref=64","unstructured":"GRAd-COV2 vaccine against COVID-19 - Full text view - ClinicalTrials.gov. 2021. Available from:(Accessed January 5, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04528641"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.addr.2020.12.006","volume":"169","author":"Batty C.J.","year":"2021","unstructured":"Batty C.J.; Heise M.T.; Bachelder E.M.; Ainslie K.M.; Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Adv Drug Deliv Rev Published online ahead of print, 2020 Dec 132021,169,168-189","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=66","unstructured":"COVID-19 vaccination using a 2nd generation (E1\/E2B\/E3-Deleted) Adenoviral-COVID-19 in nor- 140 Recent Patents on Biotechnology, 2022, Vol. 16, No. 2 Naz and Munir mal healthy volunteers - full text view - clinicaltrials.- gov. 2021. Available from:(Accessed July 30, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04591717"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"Krammer F.","year":"2020","unstructured":"Krammer F.; SARS-CoV-2 vaccines in development. Nature 2020,586(7830),516-527","journal-title":"Nature"},{"key":"ref=68","unstructured":"A study to evaluate safety and immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 - Full text view - clinicaltrials.gov. 2021. Available from:(Accessed August 6, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04809389"},{"key":"ref=69","unstructured":"Safety and immunity of Covid-19 aAPC Vaccine - Full text view - ClinicalTrials.gov. 2021. Available from:(Accessed August 6, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04299724"},{"key":"ref=70","unstructured":"Immunity and safety of Covid-19 synthetic minigene vaccine - full text view - clinicaltrials.gov. 2021. Available from:(Accessed August 6, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276896"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.29.227595","author":"Rice A.","year":"2020","unstructured":"Rice A.; Verma M.; Shin A.; A next generation bivalent human Ad5 COVID-19 Vaccine delivering both spike and nucleocapsid antigens elicits Th1 Dominant CD4+, CD8+ T-cell and neutralizing anti-body responses. BioRxiv 2020","journal-title":"BioRxiv"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/cei.13517","volume":"202","author":"Tregoning J.S.","year":"2020","unstructured":"Tregoning J.S.; Brown E.S.; Cheeseman H.M.; Vac-cines for COVID-19. Clin Exp Immunol 2020,202(2),162-192","journal-title":"Clin Exp Immunol"},{"key":"ref=73","unstructured":"Dendritic cell vaccine, AV-COVID-19, to prevent COVID-19 infection - full text view - clinicaltrials.- gov. 2021. Available from:(Accessed August 7, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04690387"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","volume":"11","author":"Yahalom-Ronen Y.","year":"2020","unstructured":"Yahalom-Ronen Y.; Tamir H.; Melamed S.; A single dose of recombinant VSV-G-spike vaccine protects against SARS-CoV-2 challenge. Nat Commun 2020,11(1),6402","journal-title":"Nat Commun"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fimmu.2020.01959","volume":"2020","year":"1959","unstructured":"Fleige H, Sutter G. Published FArster R1959,2020(Aug),7","journal-title":"Published"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"922","DOI":"10.31857\/S0026898420060154","volume":"54","author":"Zaichuk T.A.","year":"2020","unstructured":"Zaichuk T.A.; Nechipurenko Y.D.; Adzhubey A.A.; The challenges of vaccine development against be-tacoronaviruses: Antibody dependent enhancement and sendai virus as a possible vaccine vector. Mol Biol (Mosk) 2020,54(6),922-938","journal-title":"Mol Biol (Mosk)"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","volume":"29","author":"Ku MW","year":"2021","unstructured":"Ku MW; Bourgine M; AuthiA(c) P, et al Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 2021,29(2),236-49.e6","journal-title":"Cell Host Microbe"},{"key":"ref=78","unstructured":"University of Helsinki and University of Eastern Finland shareholders in a Finnish COVID vaccine company | University of Helsinki. 2021. Available from:(Accessed August 8,\n2021). https:\/\/www.helsinki.fi\/en\/news\/pandemics\/university-helsinki-and-university-eastern-finland-shareholders-finnish-covid-vaccine-company"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","volume":"590","author":"Sanchez-Felipe L.","year":"2021","unstructured":"Sanchez-Felipe L.; Vercruysse T.; Sharma S.; A single-dose live-attenuated YF17D-vectored SARSCoV-2 vaccine candidate. Nature 2021,590(7845),320-325","journal-title":"Nature"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"32657","DOI":"10.1073\/pnas.2014468117","volume":"117","author":"H&#xF6;rner C.","year":"2020","unstructured":"H&#xF6;rner C.; Sch&#xFC;rmann C.; Auste A.; A highly im-munogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proc Natl Acad Sci USA 2020,117(51),32657-32666","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3390\/v12090987","volume":"12","author":"Loes A.N.","year":"2020","unstructured":"Loes A.N.; Gentles L.E.; Greaney A.J.; Crawford K.H.D.; Bloom J.D.; Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. Viruses 2020,12(9),987","journal-title":"Viruses"},{"key":"ref=82","unstructured":"UW\u2013Madison, FluGen, Bharat biotech to develop CoroFlu, a coronavirus vaccine. 2021. Available from:(Accessed January 8, 2021). https:\/\/news.wisc.edu\/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirusvaccine\/"},{"key":"ref=83","unstructured":"Press Release - Intravacc. 2021. Available from:(Accessed January 9, 2021). https:\/\/www.intravacc.nl\/news\/intravacc-partners-with- -wageningen-bioveterinary-research-and-utrecht-university-to-develop-an-intranasal-covid-19-vaccine\/"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2020.10.2020","DOI":"10.1101\/2020.10.10.331348","author":"King R.G.","year":"2020","unstructured":"King R.G.; Silva-Sanchez A.; Peel J.N.; Singledose intranasal administration of AdCOVID elicits system-ic and mucosal immunity against SARS-CoV- -2 in mice. bioRxiv 2020,2020.10.2020","journal-title":"bioRxiv"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1134\/S0026893320060151","volume":"54","author":"Zaichuk T.A.","year":"2020","unstructured":"Zaichuk T.A.; Nechipurenko Y.D.; Adzhubey A.A.; The challenges of vaccine development against be-tacoronaviruses: Antibody dependent enhancement and sendai virus as a possible vaccine vector. Mol Biol 2020,54,84-86","journal-title":"Mol Biol"},{"key":"ref=86","unstructured":"GeoVax progresses in coronavirus (COVID-19) vaccine development program. 2021. Available from:(Accessed January 12, 2021). https:\/\/www.geovax.com\/news\/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program"},{"key":"ref=87","unstructured":"SARS-CoV-2: DZIF scientists and the development of vaccines | German Center for Infection Research. 2021. Available from:(Accessed\nJanuary 12, 2021). https:\/\/www.dzif.de\/en\/sars-cov-2-dzif-scientists-and-development-vaccines"},{"key":"ref=88","unstructured":"Home | Stabilitech. 2021. Available from:(Accessed January 12,\n2021). https:\/\/www.stabilitech.com\/"},{"key":"ref=89","unstructured":"Valo therapeutics to support development of a Pan \u2013 Coronavirus vaccine | Valo therapeutics LTD. 2021. Available from:(Accessed January 12, 2021). https:\/\/www.valotx.com\/article\/valo-therapeutics-support-development-pan-coronavirus-vaccine"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41541-020-00248-6","volume":"5","author":"Kurup D.","year":"2020","unstructured":"Kurup D.; Wirblich C.; Ramage H.; Schnell M.J.; Rabies virus-based COVID-19 vaccine CORAVAX\u2122 induc-es high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines 2020,5,98","journal-title":"NPJ Vaccines"},{"key":"ref=91","author":"Swartz R.","year":"2022","unstructured":"Swartz R.;  Episomal expression of potent immunoglobulins derived from human blood or convalescent plasma to enable short term vaccination \/ immunization to COVID, COVID-19 and mutants and other pandemic and non-pandemic viruses designed from rapid FDA approval. U.S. Patents; 20220064265,2022"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"Heath P.T.","year":"2021","unstructured":"Heath P.T.; Galiza E.P.; Baxter D.N.; Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med 2021,385,1172-1183","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.22.21252091","author":"Chang-Monteagudo A.","year":"2021","unstructured":"Chang-Monteagudo A.; Ochoa-Azze R.; A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization re-sponse in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial. 2021"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.24.311027","year":"2021","unstructured":"J oshua G, Lianget S. Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. bioRxiv 2021","journal-title":"bioRxiv"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"589833","DOI":"10.3389\/fimmu.2020.589833","volume":"11","author":"Liang Z.","year":"2020","unstructured":"Liang Z.; Zhu H.; Wang X.; Adjuvants for coro-navirus vaccines. Front Immunol 2020,11,589833","journal-title":"Front Immunol"},{"key":"ref=96","doi-asserted-by":"publisher","author":"Watterson D.","unstructured":"Watterson D.; Wijesundara D.; Modhiran N.; Mo-lecular clamp stabilized Spike protein for protection against SARS- CoV-2.","DOI":"10.21203\/rs.3.rs-68892\/v1."},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"20085","DOI":"10.1038\/s41598-020-77077-z","volume":"10","author":"Kuo T.Y.","year":"2020","unstructured":"Kuo T.Y.; Lin M.Y.; Coffman R.L.; Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep 2020,10(1),20085","journal-title":"Sci Rep"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.vaccine.2021.01.044","volume":"39","author":"Su Q.D.","year":"2021","unstructured":"Su Q.D.; Zou Y.N.; Yi Y.; Recombinant SARSCoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response. Vaccine 2021,39(8),1241-1247","journal-title":"Vaccine"},{"key":"ref=99","unstructured":"Instituto finlay de Vacunas Cuba: FINLAY-FR-2 \u2013 COVID19 vaccine tracker. 2021. Available from:(Accessed\nFebruary 5, 2021). https:\/\/covid19.trackvaccines.org\/vaccines\/52\/"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"Wang N.","year":"2020","unstructured":"Wang N.; Shang J.; Jiang S.; Du L.; Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 2020,11(298)","journal-title":"Front Microbiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"Dai L.","year":"2020","unstructured":"Dai L.; Zheng T.; Xu K.; A universal design of Betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020,182(3),722-733.e11","journal-title":"Cell"},{"key":"ref=102","unstructured":"Anhui Zhifei Longcom: RBD-Dimer \u2013 COVID19 Vaccine Tracker. Available from:(Accessed February\n5, 2021).2021. https:\/\/covid19.-trackvaccines.org\/vaccines\/27\/#trial-chictr2000040153-nct04646590"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbrc.2020.06.020","volume":"529","author":"Fujita R.","year":"2020","unstructured":"Fujita R.; Hino M.; Ebihara T.; Efficient produc-tion of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system. Biochem Biophys Res Commun 2020,529(2),257-262","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=104","unstructured":"Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19. 2021. Available from:(Accessed February 5, 2021). https:\/\/www.gsk.com\/en-gb\/media\/- press-releases\/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19\/"},{"key":"ref=105","unstructured":"Vaccine Program COVAXX. 2021. Available from:(Accessed February\n5, 2021). https:\/\/www.covaxx.com\/vaccine"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"Keech C.","year":"2020","unstructured":"Keech C.; Albert G.; Cho I.; Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020,383(24),2320-2332","journal-title":"N Engl J Med"},{"key":"ref=107","unstructured":"COVID-19 \u2013 BaiyaPhytopharm. 2021. Available from:(Accessed\nAugust 10, 2021). https:\/\/baiyaphytopharm.com\/covid-19\/"},{"key":"ref=108","unstructured":"COVID-19 \u2013 BaiyaPhytopharm. BaiyaPhytopharm.Published\n2021. Accessed August 10, 2021 https:\/\/baiyaphytopharm.com\/covid-19\/"},{"key":"ref=109","unstructured":"Neo7Logix precision bio-science. Available from:(Accessed February 6,\n2021).2021. https:\/\/neo7logix.com\/"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"100025","DOI":"10.1074\/jbc.RA120.016284","volume":"296","author":"Malladi S.K.","year":"2021","unstructured":"Malladi S.K.; Singh R.; Pandey S.; Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. J Biol Chem 2021,296,100025","journal-title":"J Biol Chem"},{"key":"ref=111","unstructured":"Izmir biomedicine and genome center. 2021. Available from:(Accessed February 6, 2021). https:\/\/www.ibg.edu.tr\/news\/details\/- first-animal-tests-for-the-coronavirus-vaccinationgave-positive-results\/"},{"key":"ref=112","unstructured":"MIGAL\u2019s Coronavirus Vaccine Project | MIGAL - Galilee Research Institute. 2021. Available from:(Accessed February 8, 2021). https:\/\/www.migal.org.il\/en\/coronavirus-vaccine-project"},{"key":"ref=113","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-61074\/v1","author":"Liu Z","year":"2020","unstructured":"Liu Z; Xu W; Xia S;  The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection 2020","journal-title":"The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection"},{"key":"ref=114","unstructured":"Adaptvac. Successful manufacture of COVID-19 Cvlp vaccine. 2021. Availoable from:https:\/\/8b308f56-ce2d-4857-87a8-\n461fb5387ef7.filesusr.- 142 Recent Patents on Biotechnology,\n2022, Vol. 16, No. 2 Naz and Munir\ncom\/ugd\/d53985_9026ed5a52774bf6ad0af2b04b35d\n342.pdf (Accessed July 30, 2021)."},{"key":"ref=115","unstructured":"IMV reports update on COVID-19 vaccine program. 2021. Available from:Accessed\nFebruary 7, 2021). https:\/\/www.imv-inc.com\/investors\/press-releases\/detail\/673\/imv-reports-update-on-covid-19-vaccine-program"},{"key":"ref=116","unstructured":"EPV-CoV19: HCW Vaccine - EpiVax, Inc. - informatics, and immunology. EpiVax, Inc. - informatics and immunology. 2021. Available from:(Accessed\nFebruary 7, 2021). https:\/\/epivax.com\/pipeline\/epv-cov19"},{"key":"ref=117","unstructured":"OncoGen researchers propose personalized vaccinomics strategy for the novel China coronavirus \u2013 OncoGen Timi\u0219oara. 2021. Available from:(Accessed February 8, 2021). https:\/\/oncogen.ro\/oncogen-vaccine-design-for-coronavirus\/"},{"key":"ref=118","unstructured":"WRAIR announces COVID-19 vaccine candidate, targets clinical trial date. 2021. Available from: date (Accessed February 7, 2021). www.army.mil Available from:"},{"key":"ref=119","unstructured":"COVID-19. 2021. Available from:(Accessed February 7, 2021). https:\/\/www.-.ge-nerex.com\/covid-19"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"102743","DOI":"10.1016\/j.ebiom.2020.102743","volume":"55","author":"Kim E.","year":"2020","unstructured":"Kim E.; Erdos G.; Huang S.; Microneedle array delivered recombinant coronavirus vaccines: Immu-nogenicity and rapid translational development. EBioMedicine 2020,55,102743","journal-title":"EBioMedicine"},{"key":"ref=121","unstructured":"Heat biologics announces completion of ZVX-60 vaccine cell line for COVID-19. heat biologics. 2021. Available from: https:\/\/www.heatbio.- com\/newsmedia\/ news-releases\/detail\/676\/heat-biologicsannounces- completion-of-zvx-60-vaccine-cell.(Accessed\nFebruary 7, 2021)."},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1038\/s41598-020-67023-4","volume":"10","author":"Evtushenko E.A.","year":"2020","unstructured":"Evtushenko E.A.; Ryabchevskaya E.M.; Nikitin N.A.; Atabekov J.G.; Karpova O.V.; Plant virus particles with various shapes as potential adjuvants. Sci Rep 2020,10,10365","journal-title":"Sci Rep"},{"key":"ref=123","unstructured":"Quadram researchers working on the COVID-19 vaccine join WHO expert groups - Quadram Institute. Quadram Institute. 2021. Available from https:\/\/quadram.ac.uk\/quadram-researchers-working-oncovid-19-vaccine-join-who-expert-groups\/"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1016\/j.vaccine.2020.06.066","volume":"38","author":"Ren W.","year":"2020","unstructured":"Ren W.; Sun H.; Gao G.F.; Recombinant SARSCoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman pri-mates. Vaccine 2020,38(35),5653-5658","journal-title":"Vaccine"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-662-45024-6_2","author":"Sanders B.","year":"2014","unstructured":"Sanders B.; Koldijk M.; Schuitemaker H.;  Inactivated viral vaccines Vaccine Analysis: Strategies 2014,45-80","journal-title":"Inactivated viral vaccines Vaccine Analysis: Strategies"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Zhang Y.","year":"2021","unstructured":"Zhang Y.; Zeng G.; Pan H.; Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a ran-domised, double-blind, placebo- controlled, phase 1\/2 clinical trial. Lancet Infect Dis 2021,21(2),181-192","journal-title":"Lancet Infect Dis"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"Tanriover MD","year":"2021","unstructured":"Tanriover MD; Do&#x17D;Yanay HL, Akova M, et al. CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, ran-domised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021,398(10296),213-222","journal-title":"Lancet"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"Xia S.","year":"2020","unstructured":"Xia S.; Duan K.; Zhang Y.; Effect of an inactivat-ed vaccine Against SARS-CoV-2 on safety and im-munogenicity outcomes: Interim analysis of 2 ran-domized clinical trials. JAMA 2020,324(10),951-960","journal-title":"JAMA"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"Xia S.","year":"2021","unstructured":"Xia S.; Zhang Y.; Wang Y.; Safety and immuno-genicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-- controlled, phase 1\/2 trial. Lancet Infect Dis 2021,21(1),39-51","journal-title":"Lancet Infect Dis"},{"key":"ref=130","unstructured":"Sinopharm [Vero Cell]- Inactivated, COVID-19 vaccine. 2021. Available from:(Accessed August 13, 2021). https:\/\/www.who.int\/publications\/m\/item\/sinopharm-vero-cell-inactivated-covid-19-vaccine"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"Ella R.","year":"2021","unstructured":"Ella R.; Reddy S.; Jogdand H.; Safety and immu-nogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomized, phase 1 trial. Lancet Infect Dis 2021,21(7),950-961","journal-title":"Lancet Infect Dis"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1101\/2020.12.21.20248643","volume":"21","author":"Ella R.","year":"2021","unstructured":"Ella R.; Reddy S.; Jogdand H.; Safety and immu-nogenicity clinical trial of an inactivated SARSCoV-2 vaccine, BBV152 (a phase 2, double-blind, random-ized controlled trial) and the persistence of immune responses from a phase 1 follow-up report. Lancet Infect Dis 2021,21(7),950-961","journal-title":"Lancet Infect Dis"},{"key":"ref=133","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.27.20189548","author":"Pu J.","year":"2020","unstructured":"Pu J.; Yu Q.; Yin Z.; An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine. BioRxiv 2020","journal-title":"BioRxiv"},{"key":"ref=134","unstructured":"COVID-19 VLA2001 Valneva. 2021. Available from:(Accessed February 12, 2021). https:\/\/valneva.com\/research-development\/- covid-19-vla2001\/"},{"key":"ref=135","unstructured":"IRCT | A double-blinded, randomized, placebocontrolled Phase I Clinical trial to evaluate the safety and immunogenicity of COVID-19 inactivated vaccine (Shif-Pharmed) in a healthy population. Contributing Vaccine Technologies for SARS-CoV-2 Recent Patents on Biotechnology, 2022, Vol. 16, No. 2 143 2021. Available from:(Accessed February 12, 2021). https:\/\/en.irct.ir\/trial\/52701"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","volume":"17","author":"Donaldson B.","year":"2018","unstructured":"Donaldson B.; Lateef Z.; Walker G.F.; Young S.L.; Ward V.K.; Virus-like particle vaccines: immunology and formulation for clinical translation. Expert Rev Vaccines 2018,17(9),833-849","journal-title":"Expert Rev Vaccines"},{"key":"ref=137","unstructured":"VLP technologies and production platform. 2021.Available from:(Accessed February 13, 2021). https:\/\/www.medicago.com\/en\/technologies\/#production-platform"},{"key":"ref=138","unstructured":"Study of a recombinant coronavirus-like particle COVID-19 vaccine in adults - full text view - clinicaltrials. gov. 2021. Available from(Accessed February 13, 2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04636697"},{"key":"ref=139","unstructured":"Spybiotech 2021. Available from:(Accessed February 13, 2021). https:\/\/www.spybiotech.com\/media\/uploads\/files\/SpyBiotech_Corporate_Factsheet_Public_V5_-_26.10.20_1.pdf"},{"key":"ref=140","unstructured":"COVID-19 - Codagenix 2021. Available from:(Accessed February 13, 2021). https:\/\/codagenix.com\/vaccine-programs\/covid-19\/"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","volume":"118","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Yang C.; Song Y.; Scalable live-attenuated SARS-CoV-2 vaccine candidate demon-strates preclinical safety and efficacy. Proc Natl Acad Sci USA 2021,118(29),e2102775118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=142","author":"Moore T","unstructured":"Moore T; Moore C.;  HCoV vaccine for improving immunity against SARS-CoV-2 infection. U.S. Patent; 11058764, July 17, 2022."},{"key":"ref=143","unstructured":"Science. OSIVAX. 2021. Available from:(Accessed February\n13, 2021). http:\/\/www.osivax.com\/science.html"},{"key":"ref=144","unstructured":"ARTES joins global combat against Corona - ARTES Biotechnology. 2021. Available from:(Accessed February 13, 2021). https:\/\/artes-biotechnology.biz\/artes-joins-global-combat- -against-corona\/"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"eaaw2853","DOI":"10.1126\/sciadv.aaw2853","volume":"5","author":"Vragniau C","year":"2019","unstructured":"Vragniau C; Bufton Jc, Garzoni F, et al Synthetic self-assembling ADDomer platform for highly effi-cient vaccination by the genetically encoded multie-pitope display. Sci Adv 2019,5(9),eaaw2853","journal-title":"Sci Adv"}],"container-title":["Recent Patents on Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872208316666220118094344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200318\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1872208316666220118094344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:03:16Z","timestamp":1691726596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200318\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":145,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872208316666220118094344","relation":{},"ISSN":["1872-2083"],"issn-type":[{"value":"1872-2083","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}